Comvita (CVT) H2 2025 earnings summary

Executive summary

• FY25 revenue declined 4.1% to $192.4 million, with a net loss after tax of $104.8 million, reflecting significant impairments, provisioning, and persistent market and operational headwinds, especially in China.

• Sector pressures included weakening demand, changing consumer preferences, oversupply, and capital constraints.

• Tangible progress included positive free cash flow, reduced net debt, disciplined inventory and cost management, and a signed Scheme Implementation Agreement (SIA) with Florenz at $0.80 per share, offering a premium to recent prices.

• Leadership changes included a new CEO and ongoing CFO recruitment, with a focus on operational reset and improved performance.

Financial highlights

• Revenue for FY25 was $192.4 million, down 4.1% year-over-year, with gross profit of $82.7 million (down 24%).

• Underlying NPBT loss was $21.9 million; reported NPAT loss was $104.8 million, including $53.9 million in impairments and $15.1 million in inventory provisions.

• Operating cash flow improved to $34.1 million, up $28.8 million year-over-year; free cash flow was $25.3 million, up 273.2%.

• Net debt reduced to $62.4 million (down $17.4 million); inventory reduced by 34.4% to $89.0 million.

• Operating expenses decreased by $11.4 million (9%) year-over-year, with $12.6 million in cost savings.

Outlook and guidance

• No formal forward guidance provided; an independent appraiser's report will be available in October.

• FY26 focus is on returning to profitability, further cost savings, and strengthening the balance sheet, contingent on execution and bank support.

• Priorities include reducing net debt, improving gross profit, growing share in lower UMF grades, and ongoing OpEx savings.

• Board signals need for long-term recapitalisation if the Scheme with Florenz does not proceed.